Dr. Jeremy Shefner, chair of the Department of Neurology at Barrow, recently presented the results of the FORTITUDE-ALS trial at the annual meeting of the American Academy of Neurology in Philadelphia.

The Phase 2 trial evaluated a drug called reldesemtiv in patients with amyotrophic lateral sclerosis.

While the trial did not meet statistical significance for primary efficacy analysis, patients on all doses of the drug declined less than patients on placebo.

Read the press release here: Cytokinetics announces results of FORTITUDE-ALS